Matches in SemOpenAlex for { <https://semopenalex.org/work/W1030887039> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W1030887039 endingPage "685" @default.
- W1030887039 startingPage "679" @default.
- W1030887039 abstract "AIM: To evaluate the clinical efficacy of salvianolic acidB (SA-B) on liver fibrosis in chronic hepatitis B.METHODS: Sixty patients with definite diagnosis of liverfibrosis with hepatitis B were included in the trial.Interferon-γ (IFN-γ) was used as control drug. Thepatients took orally SA-B tablets or received muscularinjection of IFN-γ in the double blind randomized test,The complete course lasted 6 months. The histologicalchanges of liver biopsy specimen before and after thetreatment were the main evidence in evaluation, incombination with the results of contents of serum HA,LN, Ⅳ-C, P-Ⅲ-P, liver ultrasound imaging, andsymptoms and signs.RESULTS: Reverse rate of fibrotic stage was 36.67 % inSA-B group and 30.0 % in IFN-γgroup. Inflammatoryalleviating rate was 40.0 % in SA-B group and 36.67 %in IFN-γ group. The average content of HA and Ⅳ-Cwas significantly lower than that before treatment. Theabnormal rate also decreased remarkably. Overallanalysis of 4 serological fibrotic markers showedsignificant improvement in SA-B group as comparedwith the IFN-γgroup. Score of liver ultrasound imagingwas lower in SA-B group than in IFN-γgroup (HA 36.7 %vs80 %,Ⅳ-C 3.3 % vs23.2 %). Before the treatment,ALT AST activity and total bilirubin content of patientswho had regression of fibrosis after oral administrationof SA-B, were significantly lower than those of patientswho had aggravation of fibrosis after oraladministration of SA-B. IFN-γ showed certain sideeffects (fever and transient decrease of leukocytes,occurrence rates were 50 % and 3.23 %), but SA-Bshowed no side effects.CONCLUSION: SA-B could effectively reverse liverfibrosis in chronic hepatitis B. SA-B was better than IFN-γ in reduction of serum HA content, overall decrease of4 serum fibrotic markers, and decrease of ultrasoundimaging score. Liver fibrosis in chronic hepatitis B withslight liver injury was more suitable to SA-B in anti-fibrotic treatment. SA-B showed no obvious side effects." @default.
- W1030887039 created "2016-06-24" @default.
- W1030887039 creator A5005425977 @default.
- W1030887039 creator A5016435193 @default.
- W1030887039 date "2002-01-01" @default.
- W1030887039 modified "2023-09-24" @default.
- W1030887039 title "Clinical observation of salvianolic acid Bin treatment of liver fibrosis in chronic hepatitisB" @default.
- W1030887039 hasPublicationYear "2002" @default.
- W1030887039 type Work @default.
- W1030887039 sameAs 1030887039 @default.
- W1030887039 citedByCount "0" @default.
- W1030887039 crossrefType "journal-article" @default.
- W1030887039 hasAuthorship W1030887039A5005425977 @default.
- W1030887039 hasAuthorship W1030887039A5016435193 @default.
- W1030887039 hasConcept C126322002 @default.
- W1030887039 hasConcept C2775934546 @default.
- W1030887039 hasConcept C2777382497 @default.
- W1030887039 hasConcept C2777766500 @default.
- W1030887039 hasConcept C2777785397 @default.
- W1030887039 hasConcept C2780559512 @default.
- W1030887039 hasConcept C2780678043 @default.
- W1030887039 hasConcept C71924100 @default.
- W1030887039 hasConcept C90924648 @default.
- W1030887039 hasConceptScore W1030887039C126322002 @default.
- W1030887039 hasConceptScore W1030887039C2775934546 @default.
- W1030887039 hasConceptScore W1030887039C2777382497 @default.
- W1030887039 hasConceptScore W1030887039C2777766500 @default.
- W1030887039 hasConceptScore W1030887039C2777785397 @default.
- W1030887039 hasConceptScore W1030887039C2780559512 @default.
- W1030887039 hasConceptScore W1030887039C2780678043 @default.
- W1030887039 hasConceptScore W1030887039C71924100 @default.
- W1030887039 hasConceptScore W1030887039C90924648 @default.
- W1030887039 hasIssue "4" @default.
- W1030887039 hasLocation W10308870391 @default.
- W1030887039 hasOpenAccess W1030887039 @default.
- W1030887039 hasPrimaryLocation W10308870391 @default.
- W1030887039 hasRelatedWork W13742046 @default.
- W1030887039 hasRelatedWork W20724912 @default.
- W1030887039 hasRelatedWork W2115991121 @default.
- W1030887039 hasRelatedWork W2350323459 @default.
- W1030887039 hasRelatedWork W2351173839 @default.
- W1030887039 hasRelatedWork W2354231939 @default.
- W1030887039 hasRelatedWork W2361746319 @default.
- W1030887039 hasRelatedWork W2364863973 @default.
- W1030887039 hasRelatedWork W2368664495 @default.
- W1030887039 hasRelatedWork W2369768391 @default.
- W1030887039 hasRelatedWork W2369834724 @default.
- W1030887039 hasRelatedWork W2371528101 @default.
- W1030887039 hasRelatedWork W2373273299 @default.
- W1030887039 hasRelatedWork W2378909332 @default.
- W1030887039 hasRelatedWork W2380214252 @default.
- W1030887039 hasRelatedWork W2380584415 @default.
- W1030887039 hasRelatedWork W2383817969 @default.
- W1030887039 hasRelatedWork W2387711728 @default.
- W1030887039 hasRelatedWork W2390069222 @default.
- W1030887039 hasRelatedWork W2978247777 @default.
- W1030887039 hasVolume "8" @default.
- W1030887039 isParatext "false" @default.
- W1030887039 isRetracted "false" @default.
- W1030887039 magId "1030887039" @default.
- W1030887039 workType "article" @default.